We previously demonstrated that transcranial delivery of NIR for 4 weeks decreases synaptic vulnerability to Aβ and Tau toxic oligomers in the hippocampus and cortex of different AD-like mouse models69,70, while other groups demonstrated its effectiveness in reducing neuroinflammation in animal models of TBI or genetic models of Aβ-pathology111–113. The gene discussed is MAPT; the disease is Alzheimer disease.